BVT-0448-C200200 µgCHF 120.00
BVT-0448-M0011 mgCHF 190.00
BVT-0448-M0055 mgCHF 590.00
|Source/Host Chemicals||Isolated from Aspergillus terreus.|
|Purity Chemicals||≥98% (HPLC, NMR)|
|Appearance||White to off-white solid.|
|Solubility||Soluble in DMSO, methanol, ethanol or acetone.|
|Identity||Determined by 1H-NMR.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Protect from light when in solution.|
Stable for at least 1 year after receipt when stored at +4°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
- Cell permeable, potent and selective cyclin-dependent kinase CDK-1 (CDC2), -2 and -5 inhibitor [1-4, 9, 10].
- Apoptosis inducer [6, 7, 9].
- Antitumor agent [5, 9].
- Inhibits cell cycle progression at the G1/S and G2/M transitions .
- Shown to prevent the phosphorylation of retinoblastoma protein and H1 histone [2, 10].
- Important probe for understanding the cellular roles of CDKs .
- Inhibitor of α-glucosidases .
- Maturation inhibitor of sheep oocytes .
- Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase: M. Kitagawa, et al.; Oncogene 8, 2425 (1993)
- A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression: M. Kitagawa, et al.; Oncogene 9, 2549 (1994)
- Evidence for cdk5 as a major activity phosphorylating tau protein in porcine brain extract: T. Hosoi, et al.; J. Biochem. 117, 741 (1995)
- Chemical inhibitors of cyclin-dependent kinases: L. Meijer; Prog. Cell Cycle Res. 1, 351 (1995) (Review)
- Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines: K. Nishio, et al.; Anticancer Res. 16, 3387 (1996)
- Transcriptional activation of the cdc2 gene is associated with Fas- induced apoptosis of human hematopoietic cells: Y. Furukawa, et al.; J. Biol. Chem. 271, 28469 (1996)
- An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells: M. Wada, et al.; Anticancer Res. 18, 2559 (1998)
- Butyrolactone I induces cyclin B1 and causes G2/M arrest and skipping of mitosis in human prostate cell lines: M. Suzuki, et al.; Cancer Lett. 138, 121 (1999)
- Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis: H. Lin, et al.; J. Biol. Chem. 279, 29302 (2004)
- Regulation of mitotic function of Chk1 through phosphorylation at novel sites by cyclin-dependent kinase 1 (Cdk1): T. Shiromizu, et al.; Genes Cells 11, 477 (2006)
- Butyrolactone-I reversibly inhibits but does not improve the maturation and subsequent development of sheep oocytes in vitro: L. Lu, et al.; J. Animal Vet. Adv. 12, 17 (2013)
- Effect on α-glucosidase inhibition and antioxidant activities of butyrolactone derivatives from Aspergillus terreus MC751: R. Dewi, et al.; Med. Chem. Res. 23, 454 (2014)